Lv1
40 积分 2024-09-25 加入
[Chinese expert consensus on diagnosis, treatment and prevention of pulmonary infection in patients with solid tumors (2024 edition)]
12小时前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
15天前
已完结
[Chinese expert consensus on treatment of malignant pleural effusion (2023 Edition)]
3个月前
已完结
[Expert consensus on standardized management of taxane-related peripheral neuropathy]
3个月前
已完结
Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes
3个月前
已完结
[Chinese expert consensus on clinical testing standards of PD-L1 expression for non-small cell lung cancer (2023 version)]
3个月前
已完结
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non–Small-Cell Lung Cancer
4个月前
已完结
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up
4个月前
已完结
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
5个月前
已完结
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
